Jin Guangchao, Han Yu, Liu Cun, Chen Liansheng, Ding Butong, Xuan Shijin, Liu Xianqiang, Ma Guohui, Gao Jun, Tian Xingsong
Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
Intensive Care Unit, Shan Dong Province Hospital, Shandong University Jinan 250012, P.R. China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):914-21. eCollection 2015.
To assess the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 expression in breast cancer patients after various neoadjuvant chemotherapies. Data from 138 locally advanced breast cancer patients with histological diagnoses were reviewed. Seventy patients (group 1) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 50 mg/m(2) pirarubicin every 21 days. Sixty-eight patients (group 2) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 75 mg/m(2) docetaxel every 21 days. The biomarker changes of the operated tumor tissues were compared with the initial core biopsies. ER, PR, HER2 and Ki-67 expression changed by 28.6%, 22.9%, 17.1% and 54.3%, respectively, after neoadjuvant chemotherapy in group 1 and 16.2%, 22.1%, 13.2% and 70.6%, respectively, after neoadjuvant chemotherapy in group 2. There were significant differences between the groups regarding ER and Ki-67 status changes, and these changes can be used to inform treatment strategies.
评估不同新辅助化疗后乳腺癌患者雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER2）和Ki-67表达的变化。回顾了138例经组织学诊断的局部晚期乳腺癌患者的数据。70例患者（第1组）每21天接受4个周期的500mg/m²环磷酰胺和50mg/m²吡柔比星治疗。68例患者（第2组）每21天接受4个周期的500mg/m²环磷酰胺和75mg/m²多西他赛治疗。将手术切除肿瘤组织的生物标志物变化与最初的核心活检结果进行比较。第1组新辅助化疗后，ER、PR、HER2和Ki-67表达分别变化了28.6%、22.9%、17.1%和54.3%；第2组新辅助化疗后，这些指标分别变化了16.2%、22.1%、13.2%和70.6%。两组在ER和Ki-67状态变化方面存在显著差异，这些变化可用于指导治疗策略。
